• About Us
  • Contact
  • Cookie Policy
  • Disclaimer
  • Privacy Policy
  • Editorial Charter
  • Corrections Policy
  • Sitemap
Freelanews
Advertisement
  • Home
  • News
    • Crime
  • Business
  • Brands
  • Banking
  • Opinion
  • Interview
  • Entertainment
  • Podcast
    • Àtẹ́lẹwọ́
  • Sports
  • Events
No Result
View All Result
  • Home
  • News
    • Crime
  • Business
  • Brands
  • Banking
  • Opinion
  • Interview
  • Entertainment
  • Podcast
    • Àtẹ́lẹwọ́
  • Sports
  • Events
No Result
View All Result
Freelanews
No Result
View All Result
Home News General

Is new bivalent COVID-19 vaccine the booster we’ve been waiting for?

Quadri Olaitan by Quadri Olaitan
September 18, 2023
in General
0 0
0
cov jpg
thenacre-campaign

In a recent study published in The Lancet Respiratory Medicine, researchers evaluated the efficacy of a bivalent recombinant protein vaccine for coronavirus disease 2019 (COVID-19).

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were initially developed using the spike sequence from the ancestral strain, which is less effective against emerging variants of concern (VOCs). Therefore, updated vaccines have been developed to protect against the emergent VOCs.

GlaxoSmithKline (GSK) and Sanofi developed a bivalent vaccine (CoV2 preS dTM-AS03 [D614 + B.1.351]) containing stabilized pre-fusion spike proteins from the ancestral D614 strain and the Beta VOC (B.1.351) with the AS03 adjuvant system.

The vaccine is being assessed as a two-dose primary series in non-vaccinated individuals and as a booster in people with a prior infection. Results from the phase 2 study demonstrated robust immunogenicity and acceptable reactogenicity and safety in people naïve and non-naïve for SARS-CoV-2, supporting further evaluation.

About the study

Perfect-Aesthetic-social-1

In the present study, researchers presented data on the clinical safety and efficacy of the bivalent CoV2 preS dTM-AS03 (D614 + B.1.351) vaccine as the primary series. This randomized, double-blind, phase 3, placebo-controlled trial had two stages. The first stage evaluated the efficacy of a prototype monovalent vaccine, and the second stage explored the bivalent vaccine. Data from the second stage were reported in this study.

Participants were recruited from eight countries between October 19, 2021, and February 15, 2022. Eligible subjects were non-vaccinated adults aged 18 or older. Data on medical history and race/ethnicity were self-reported at enrolment. Participants were randomized to receive the vaccine or placebo. The vaccine group received 0.5 ml injections containing 5 μg D614 and 5 μg B.1.351 antigens at days 1 and 22.

The placebo group received 0.9% normal saline. Nasopharyngeal swabs and blood specimens were obtained before each vaccination. Participants were contacted weekly to determine if they tested COVID-19-positive or had symptoms of a COVID-19-like illness. Naïve and non-naïve status was ascertained by electrochemiluminescence immunoassays.

Nucleic-acid amplification tests were performed to detect the viral nucleic acids in nasopharyngeal swabs. The primary endpoint was vaccine efficacy in preventing symptomatic COVID-19 ≥ 14 days after the second dose in all participants. Secondary endpoints were symptomatic illness in non-naïve and naïve subjects, disease severity, and hospitalization after the second dose.
Findings

The researchers enrolled and randomized 13,506 individuals and excluded 504 subjects from analyses due to incomplete data from Ukrainian sites. The vaccine group comprised 6,515 participants, and the placebo group had 6,490 subjects. The modified full analysis set included 11,416 participants who received two injections. In total, 12,924 subjects received at least one injection.

adron lemon friday

The mean age of participants was 36.1; 58.4% were males, and 32.2% had high-risk medical conditions. About 75% of participants were non-naïve at enrolment. Within the modified full analysis set, 121 cases of symptomatic COVID-19 were reported ≥ 14 days after the second dose, and the overall vaccine effectiveness was 64.7%. Placebo recipients showed a higher cumulative incidence of COVID-19 than vaccinees.

Five cases developed severe illness, 12 had moderate or worse illness, and two subjects required hospitalization. No deaths occurred due to COVID-19. Vaccine efficacy against symptomatic disease in non-naïve subjects was over 75%, but 30.9% in naïve subjects. Overall, the efficacy against symptomatic illness was 60.3% after the first dose. Efficacy against asymptomatic infection was 1.2%.

Vaccine efficacy was generally higher in males. The causal variant was determined in 68 cases, with the Omicron sub-variants (BA.1 and BA.2) causing 64 cases. The Omicron-specific efficacy was 72.5% in all subjects, 20.4% in naïve participants, and 93.9% in non-naïve individuals. There were five cases of the Delta variant, all in placebo recipients. Seven placebo recipients and four vaccinees had immediate unsolicited adverse events.

Solicited adverse reactions occurred in 1,398 vaccinees and 983 placebo subjects within seven days after any injection. Both groups had similar proportions of medically-attended adverse events. Adverse events of special interest, serious adverse events, and deaths occurred in less than 1% of participants and were unrelated to treatment. There were no reports of myocarditis, pericarditis, Guillain-Barré syndrome, Bell’s Palsy, or thrombosis with thrombocytopenia.

Conclusions

Taken together, the trial met the primary objective, demonstrating efficacy against symptomatic COVID-19. The effectiveness of 75.9% against symptomatic disease in non-naïve subjects is particularly relevant. The findings suggest the vaccine could be a potential booster at a time when most of the population is already exposed to the virus or vaccinated.

Quadri Olaitan
Quadri Olaitan

Quadri Olaitan is a journalist and contributor to Freelanews.com, covering news, public affairs, and human-interest stories.

Related Posts

Huso el Dalner, al-Qaeda, manifiestismo, actualidad, conferencias, eventos, reuniones, congresos, asamblea, participación, público, participación en eventos políticos y sociales, público en un gran auditorio, reunión masiva, parlamentarios, política, democracia, multiculturalismo, asistencia a conferencias, formación política.
General

WAEC CBT suspension draws strong intervention from lawmakers

by David Okere
November 14, 2025
untitled 1
General

‘Unprecedented!’ Leke Pitan extols Tinubu transformation in Lagos health sector

by Rtn. Victor Ojelabi
December 22, 2022
Oyedepo 0
General

‘It fades to white’ Bishop Oyedepo opens up on reason he only wears one color of suit

by Freelanews
August 7, 2021
9517487 dapoabiodunbiographydapoabiodunbiographyandprofilepoliticianpoliticalleadernigeriagovernornigerian jpege48fe10ecb92ca9b4fc7dca5f88c4cc1
General

‘It is disgusting’ PDP slams Abiodun for distributing noodles, rice to victims of herdsmen attacks

by Freelanews
March 1, 2021
Lagos State House of Assembly 1200x800 1
General

‘Discord!’ INEC panel moves to clear rejected nominee, fuels vexation in Senate

by Freelanews
July 15, 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Tiktok Community

You're not logged into Tiktok, please login here
UBA bank ad UBA bank ad UBA bank ad

Recent News

UPS & COPA

UPS and Copa planes collide at Miami airport

November 16, 2026
AMAA jury

AMAA jury president urges african filmmakers to be original

November 16, 2026
images 2026 11 16T133548.238

Plateau troops kill suspected terrorist in Wase clash

November 16, 2026
Igini urges

Igini urges Trump to tie Nigeria-US relations to 2027 polls

November 16, 2026
  • Trending
  • Comments
  • Latest
N250k signature

Abiodun vs Amosun: N250k signature plot deepens Ogun political crisis ahead Tinubu visit

April 3, 2026
#image_title

17 mobile money operator companies licensed by CBN in Nigeria

March 22, 2023
Omoge Saida

Omoge Saida sparks Nigerian social media over leaked video

October 28, 2025
Australia

Ifeoma playfully reacts as Paul Okoye receives recognition in Australia

April 24, 2026
amoke

‘Meals by Amoke’ We serve traditional dishes in a modern way, Bukoye Fasola reveals

19
Image 2024 03 26 at 120645 AM jpeg

Charles Inojie, Ali Nuhu call on communities to #MakeWeHalla against domestic violence

11
Meran Primary Health Centre Lagos father Meran hospital

Lagos father shares heartbreaking experience at Meran Primary Health Centre (Photos)

4
fls2

‘Disarticulated system’ Gov’t confused about Nigerian education, expert laments

3
UPS & COPA

UPS and Copa planes collide at Miami airport

November 16, 2026
AMAA jury

AMAA jury president urges african filmmakers to be original

November 16, 2026
images 2026 11 16T133548.238

Plateau troops kill suspected terrorist in Wase clash

November 16, 2026
Igini urges

Igini urges Trump to tie Nigeria-US relations to 2027 polls

November 16, 2026
ADVERTISEMENT
November 2026
S M T W T F S
1234567
891011121314
15161718192021
22232425262728
2930  
« Oct    
Freelanews

Freelanews is a Nigerian digital news platform that delivers timely, credible, and engaging stories across politics, business, entertainment, lifestyle, and the creative industry, with a strong focus on promoting innovation, integrity, and inclusivity in storytelling.

Today’s Popular

  • quotes 22

    ‘Breaking News’ Babatunde Omidina, Baba Suwe, is dead

    0 shares
    Share 0 Tweet 0
  • 17 mobile money operator companies licensed by CBN in Nigeria

    0 shares
    Share 0 Tweet 0
  • Ifeoma playfully reacts as Paul Okoye receives recognition in Australia

    0 shares
    Share 0 Tweet 0
  • Who is Rotarian Victor Ojelabi?

    0 shares
    Share 0 Tweet 0

Just Published!

UPS & COPA

UPS and Copa planes collide at Miami airport

November 16, 2026
AMAA jury

AMAA jury president urges african filmmakers to be original

November 16, 2026
images 2026 11 16T133548.238

Plateau troops kill suspected terrorist in Wase clash

November 16, 2026
Igini urges

Igini urges Trump to tie Nigeria-US relations to 2027 polls

November 16, 2026
UN chief

UN chief urges global action against killer robots

November 16, 2026
No Result
View All Result
  • About Us
  • Contact
  • Cookie Policy
  • Editorial Charter
  • Corrections Policy
  • Advertisement

© 2026 Freelanews | by Iretura.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Home
  • News
    • Crime
  • Business
  • Brands
  • Banking
  • Opinion
  • Interview
  • Entertainment
  • Podcast
    • Àtẹ́lẹwọ́
  • Sports
  • Events

© 2026 Freelanews | by Iretura.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.